Updated:
Genome Ventures
Genome Ventures is a Moscow-based private equity firm investing in early-stage life sciences, digital health, and enterprise software companies.
Genome Ventures
Genome Ventures is a venture capital firm that partners with individuals and corporations to support businesses from inception to exit. It focuses on investments in technology related to personalized healthcare, education, and communication. Genome Ventures has made three investments, including a July 2021 investment in Prolifium, and has facilitated one portfolio exit, Aizel, in November 2018.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Russia
City
Moscow
Corporate office
Moscow, Russia
Sector focus
Frequently asked questions
What investment stages does Genome Ventures target?
Genome Ventures invests across seed, venture, and growth stages, with a primary focus on early-stage companies. The firm's stated strategy emphasizes seed and Series A rounds for life-sciences startups where scientific proof-of-concept has been established. Later-stage growth capital is deployed selectively for portfolio companies reaching commercial milestones.
Which sectors does Genome Ventures specialize in?
The firm concentrates on life sciences, digital health, and enterprise software. Within life sciences, areas of focus include genomics, molecular diagnostics, therapeutics, and AI-driven drug discovery platforms. Digital health investments target regulated healthcare IT and medtech. Enterprise software exposure is limited to opportunities that intersect with the firm's core scientific and healthcare mandates.
Who runs investment decisions at Genome Ventures?
Genome Ventures does not publicly disclose its investment committee composition or senior decision-makers. The firm operates without a visible public-facing management team. This opacity is consistent with many Russia-based private investment vehicles that maintain low profiles for regulatory and commercial reasons.
Does Genome Ventures invest outside Russia?
The firm's primary geographic focus is Russia, with secondary coverage extending to Eastern Europe and Central Asia. Genome Ventures leverages proximity to Russia's research-institute and university ecosystems for deal sourcing. Cross-border investments, if any, are not publicly documented.
Is Genome Ventures structured as a venture capital fund or a private equity firm?
Genome Ventures is classified as a private equity firm operating across the venture-to-growth continuum, but its functional posture resembles a sector-specialist venture capital investor. The firm does not publicly disclose its fund structure, limited-partner base, or whether it operates evergreen or closed-end vehicles.
What is Genome Ventures' known posture on co-investments alongside external GPs?
Genome Ventures does not publicly outline a co-investment policy. In practice, early-stage life-sciences firms in Russia frequently syndicate rounds with development institutions, state-backed funds, and occasional international co-investors, but specific syndication history for Genome Ventures is unverified.
What is Genome Ventures' public track record?
The firm maintains a deliberately low public profile and does not publish portfolio-company lists, exit records, or performance metrics. No verifiable exits or realized returns are available in public record. This opacity is characteristic of Russia-based private investment firms operating outside major institutional-fundraising circles.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: